We performed a multicenter survey using a semistructured interview in 1,072 consecutive
patients with Parkinson's disease (PD) enrolled during 12 months in 55 Italian centers to …

Background Ergot-derived dopamine receptor agonists, often used in the treatment of
Parkinson's disease, have been associated with an increased risk of valvular heart disease. …

Non-motor symptoms (NMS) of Parkinson's disease remain the most under-appreciated and
under-researched when taken as a whole. Data is emerging that it is the “totaL” burden of …

Background Levodopa is the most effective therapy for Parkinson's disease, but chronic
treatment is associated with the development of potentially disabling motor complications. …

Background A Task Force was convened by the EFNS / MDS ‐ ES Scientist Panel on P
arkinson's disease ( PD ) and other movement disorders to systemically review relevant …

Background: PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria,
published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for …

To examine the variations in regional cerebral blood flow during execution and learning of
reaching movements, we employed a family of kinematically and dynamically controlled …

Objective: To assess the prevalence, nature, and associated phenotypes of PINK1 gene
mutations in a large series of patients with early-onset (<50 years) parkinsonism. Methods: The …

After more than 40 years of clinical use, levodopa (LD) remains the gold standard of
symptomatic efficacy in the drug treatment of Parkinson’s disease (PD). Compared with other …

There is extensive debate on the neurological consequences of corona virus disease 2019 (COVID-19)
and the impact this might have for patients with neurodegenerative conditions, …